Suppr超能文献

蒽环类药物诱导大鼠肥大细胞释放组胺。

Anthracycline-induced histamine release from rat mast cells.

作者信息

Riegel E A, Kaliner M, El-Hage A N, Ferrans V J, Kawanami O, Herman E H

出版信息

Agents Actions. 1982 Oct;12(4):431-7. doi: 10.1007/BF01965922.

Abstract

Comparisons were made of the ability of doxorubicin, daunorubicin, rubidazone and aclacinomycin A to release histamine from rat peritoneal mast cells. Preliminary in vitro experiments indicated that doxorubicin (10(-6) to 2.5 X 10(-4) M), in contrast to compound 48/80 and the calcium ionophore A23187, did not produce significant release under any condition tested when purified or unpurified rat mast cells were used. In in vitro experiments, released histamine was measured in the cell-free supernatant of peritoneal fluid of rats after intraperitoneal injection of the agents. The time course of doxorubicin-induced histamine release from the peritoneum was rapid, with maximal release occurring within 4 to 6 min. Dose-response curves of the 4 agents over the range 10(-5) to 3.3 X 10(-3) M revealed that all caused histamine release, with 10(-3) M concentrations of each causing maximal release of comparable magnitude to that produced by 9.5 X 10(-6) M A23187. Treated mast cells recovered from the peritoneal cavity showed degranulation and vacuolization when examined by electron microscopy. Increased vascular permeability by the Evans-blue test was also noted with all 4 agents, and zones were of comparable size after injection of the highest concentration of each agent. The results indicate that in vivo, doxorubicin, daunorubicin, rubidazone and aclacinomycin A cause a rapid release of histamine from rat mast cells and an increase in vascular permeability in rat sin. There also appeared to be a reasonable correlation between the blueing reaction and histamine release in the peritoneal cavity in that the doses that did not cause skin blueing also failed to cause histamine release. The lack of histamine release by doxorubicin from mast cell preparations in vitro suggests that alterations to the doxorubicin molecule or the presence of other critical substances may be necessary for this activity to commence.

摘要

对阿霉素、柔红霉素、鲁比唑酮和阿克拉霉素A从大鼠腹膜肥大细胞释放组胺的能力进行了比较。初步体外实验表明,与化合物48/80和钙离子载体A23187不同,当使用纯化或未纯化的大鼠肥大细胞时,阿霉素(10^(-6)至2.5×10^(-4)M)在任何测试条件下均未产生显著释放。在体外实验中,通过腹腔注射药物后,测量大鼠腹膜液无细胞上清液中释放的组胺。阿霉素诱导腹膜组胺释放的时间进程很快,最大释放在4至6分钟内发生。这4种药物在10^(-5)至3.3×10^(-3)M范围内的剂量反应曲线显示,所有药物均引起组胺释放,每种药物10^(-3)M浓度引起的最大释放量与9.5×10^(-6)M A23187产生的释放量相当。通过电子显微镜检查,从腹腔回收的经处理肥大细胞显示脱颗粒和空泡化。所有4种药物通过伊文思蓝试验也观察到血管通透性增加,注射每种药物最高浓度后形成的区域大小相当。结果表明,在体内,阿霉素、柔红霉素、鲁比唑酮和阿克拉霉素A可使大鼠肥大细胞迅速释放组胺,并使大鼠皮肤血管通透性增加。腹膜腔中变蓝反应与组胺释放之间似乎也存在合理的相关性,即未引起皮肤变蓝的剂量也未能引起组胺释放。阿霉素在体外肥大细胞制剂中不释放组胺,这表明阿霉素分子发生改变或存在其他关键物质可能是该活性开始的必要条件。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验